Status:
ACTIVE_NOT_RECRUITING
The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes
Lead Sponsor:
Asger Lund, MD
Conditions:
Type 1 Diabetes
Eligibility:
MALE
18-70 years
Phase:
NA
Brief Summary
The hormone glucose-dependent insulinotropic polypeptide (GIP) is naturally produced in the intestine during a meal and stimulates insulin secretion from the pancreas. Insulin ensures that nutrients f...
Eligibility Criteria
Inclusion
- Caucasian ethnicity
- Age between 18 and 70 years
- T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c \<69 mmol/mol (\<8.5%)
- Body mass index between 20-27 kg/m2
- T1D duration of 2-20 years
- C-peptide negative (arginin-stimulated C-peptide ≤ 100 pmol/l)
- Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months
- Informed and written consent
Exclusion
- Anaemia (haemoglobin below normal range)
- Late microvascular complications except mild nonproliferative retinopathy
- Liver disease (alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) \>2 times normal values) or history of hepatobiliary disorder
- Treatment with any glucose-lowering drugs beside insulin
- Active or recent (within 5 years) malignant disease
- Active tobacco smoking / use
- Any condition considered incompatible with participation by the investigators
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 16 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06881472
Start Date
January 1 2025
End Date
January 16 2026
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gentofte Hospital
Hellerup, Denmark, 2900